Immunodiagnostic Systems Holdings PLC provides sales guidance for the financial year ended 31 March 2020. For the year, the company reported revenue of £39.3 million.

The COVID-19 situation means there is some uncertainty surrounding the expected revenue performance in first half of 2021 and therefore the company unable to provide guidance at this time. However, the company confident once the global situation improves, the company well positioned to continue a path of revenue growth, leveraging increasing installed instrument base and assay menu.